MediciNova, Inc. (NASDAQ:MNOV)
MediciNova, Inc. (NASDAQ:MNOV) represented a move of 0 percent or $0.17 per share and closed its previous day trading session at $9.57. 0 Shares were traded in the last trading session with an Average Volume of 82.64 Million Shares. The stock currently has a Market Capitalization of 408.45 Million.
MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.
The stock traded between $ 6.09 and $14.50 over 1-Year time period showing its price to sales ratio of 0. MediciNova, Inc. (NASDAQ:MNOV) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-9.99 and 200-Day Simple Moving Average of $-8.79. Its Price to Free Cash Flow is 0 and Price to Book of 5.44.
Analyst’s recommended the stock as 1.5 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, MediciNova, Inc. (NASDAQ:MNOV) reported its Actual EPS of $-0.07/share. The analysts offering Earnings Estimates for the company were believing that MediciNova, Inc. could bring EPS of $-0.11/share. The difference between Actual EPS and Estimated EPS was 0.04 Percent. Thus showing an Earnings Surprise of 36.4 Percent.
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)
In the last trading session, Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) added its value by 0% closing at the price of $0.77. The stock currently has market capitalization of 11 Million, with average volume of 234.76 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) is showing beta of 1.32. This particular value of beta suggests that Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has historically moved 132% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) is at $-2.65.
The stock currently has RSI of 30.06. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California.
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) topped its 52-week high price of $5.920 on 01/02/18 and 52-Week Low Price of $0.760 on 11/27/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.13% and monthly volatility of 16.02% respectively.